/
XNCR
$23.75-$0.78 (-3.18%)live
Change$-9.67
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.8B
74M shares
52-week range
$8.49 – $30.61
69% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
17.2
Xencor, Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
www.xencor.com- Employees
- 260
- IPO / List date
- Dec 3, 2013
- HQ
- PASADENA, CA
Held by traders on TradeandTell
No one on the platform currently holds XNCR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 18,723 | $225.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded XNCR yet.
